13631 PROGRESS BLVD., ALACHUA, FL
Reports Fourth Quarter and Full-Year 2025 Financial Results
Announces Pricing of Upsized $124 Million Public Offering of Common Stock
Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
CFO Compensation Increase - Lindsey Hartley Receives 7% Salary Boost
Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
Reports Third Quarter 2025 Financial Results
Provides Update on FDA Review Timeline for Avance® Nerve Graft
Reports Second Quarter 2025 Financial Results
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement